Fetal Growth Restriction & Maternal Cardiovascular Risk
Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Oct 17, 2005
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND:
Intrauterine growth restriction leads to major neonatal morbidity and mortality. Moreover, recent birth registry studies have suggested that women bearing IUGR babies may have an elevated risk of cardiovascular disease.
DESIGN NARRATIVE:
This cohort study tested whether exposed women, with a previous intrauterine growth restriction (IUGR) baby, versus unexposed women, with a pregnancy not complicated by IUGR, had elevations in markers of cardiovascular risk. Exposure was defined among a geographically defined cohort as having had a singleton baby in the \< 5 %tile of weight f...
Gender
FEMALE
Eligibility criteria
- Inclusion criteria:
- • women 4 to 12 years after delivery of singleton infant
- • women who gave birth between 1997 and 2002 at Magee-Womens Hospital in Pittsburgh, Pennsylvania
- Exclusion criteria:
- • women who had preeclampsia
- • women who had prepregnancy hypertension
- • women who had diabetes
- • women who were currently pregnant or reported a prepregnancy chronic condition
About The University Of Texas Health Science Center, Houston
The University of Texas Health Science Center at Houston (UTHealth) is a leading academic institution dedicated to advancing health through education, research, and clinical practice. As a prominent sponsor of clinical trials, UTHealth leverages its extensive resources and expertise in biomedical research to facilitate innovative studies aimed at improving patient outcomes. The institution is committed to fostering a collaborative environment that promotes scientific discovery and the translation of research findings into effective healthcare solutions, all while adhering to the highest ethical standards and regulatory guidelines. With a multidisciplinary approach, UTHealth plays a critical role in addressing complex health challenges and enhancing the quality of life in diverse communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Roberta B. Ness, MD, MPH
Principal Investigator
The University of Texas Health Science Center, Houston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials